In stress models, CRH-R1 antagonists inhibited the increase of pro-inflammatory cytokines, myeloperoxidase levels, inflammatory transcription factors, colonic transit, FPO, and improved colonic morphology and urodynamic dysfunctions [25,26,36,47]. Here, CRHR1 is linked to otopalatodigital syndrome type 2.